RESOURCE LIBRARY

Advancing medicine through scientific ingenuity

RESOURCE LIBRARY

Advancing medicine science through scientific ingenuity

At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.

Filter by

CLEAR
Thursday, June 12, 2025
EHA
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients with Waldenström Macroglobulinemia
Thursday, June 12, 2025
EHA
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory CLL: Updated Findings From an Ongoing Phase 1a Study
Tuesday, April 29, 2025
American Academy of Cancer Research
Identification of Selective, Orally Bioavailable Aurora A Degraders for Treatment of Pediatric and Adult Cancers
Monday, April 28, 2025
American Association for Cancer Research (AACR) 2025 Annual Meeting
DEL-AI: Proteome-Wide In Silico Screening of Multi-Billion Compound Libraries Using Machine Learning Foundation Models
Friday, April 25, 2025
American Association for Cancer Research (AACR) 2025 Annual Meeting
NRX-0305: A Pan-Mutant BRAF Degrader with Broad Preclinical Efficacy, Brain Penetrance, and Synergistic Potential with MEK Inhibition Across Class 1/2/3 BRAF-mutant Cancers
Friday, April 25, 2025
American Association for Cancer Research (AACR) 2025 Annual Meeting
Bexobrutideg (NX-5948) is a CNS-Penetrant Catalytic Bruton’s Tyrosine Kinase (BTK) Degrader that Breaks Established Design Rules for CNS Drugs
Monday, December 9, 2024
66th American Society of Hematology (ASH) Annual Meeting
Efficacy And Safety Of The Bruton’s Tyrosine Kinase (BTK) Degrader NX-5948 In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results From An Ongoing Phase 1A/B Study
Saturday, November 16, 2024
ACR Convergence 2024
NX-5948, A Clinical-Stage BTK Degrader, Achieves Deep Suppression Of BCR, TLR, And Fcr Signaling In Immune Cells And Demonstrates Efficacy In Preclinical Models Of Arthritis And Other Inflammatory Diseases
Friday, November 15, 2024
ACR Convergence 2024
IRAK4 Degrader GS-6791 Inhibits TLR And IL-1R-Driven Inflammatory Signaling, And Ameliorates Disease In A Preclinical Arthritis Model
Wednesday, October 30, 2024
7TH Annual TPD & Induced Proximity Summit 2024
Clinical Activity of NX-5948: A First-in-Class BTK Degrader